Clinical Trials Browser

Not yet recruiting × Bevacizumab × CNS × Clear all

NCT07449481 2026-03-04

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Phase 2 Not yet recruiting

Brain Neoplasms

NCT07346157 2026-01-16

PNOC044

Phase 1/2 Not yet recruiting

Medulloblastoma

NCT06329570 2024-03-26

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1/2 Not yet recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06210438 2024-01-18

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms

NCT05540275 2023-10-06

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Phase 2 Not yet recruiting

Glioblastoma

NCT05502991 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Phase 2 Not yet recruiting

Glioblastoma